Details for Patent: 11,235,169
✉ Email this page to a colleague
Which drugs does patent 11,235,169 protect, and when does it expire?
Patent 11,235,169 protects AMELUZ and is included in one NDA.
This patent has six patent family members in six countries.
Summary for Patent: 11,235,169
| Title: | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
| Abstract: | An Illumination device (100) for photodynamic therapy is provided, the illumination device comprising at least one electromagnetic radiation emitting unit (10), the at least one electromagnetic radiation emitting unit comprising at least one electromagnetic radiation source (1), the electromagnetic radiation source being configured to generate radiation for the irradiation of a region of an irradiation object in an illumination session, wherein the irradiation object is to be arranged at a predetermined object location (300), wherein the predetermined object location is arranged at a distance relative to a radiation output area (11) of the radiation emitting unit through which the radiation generated by the at least one electromagnetic radiation source exits the radiation emitting unit during operation of the illumination device (100). |
| Inventor(s): | Osterloh; Markus (Leverkusen, DE), Novak; Ben (Leverkusen, DE), Lubbert; Hermann (Leverkusen, DE) |
| Assignee: | BIOFRONTERA PHARMA GMBH (Leverkusen, DE) |
| Application Number: | 17/215,785 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Device; |
Drugs Protected by US Patent 11,235,169
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biofrontera | AMELUZ | aminolevulinic acid hydrochloride | GEL;TOPICAL | 208081-001 | May 10, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TOPICAL LESION-DIRECTED AND FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS OF THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY BY POSITIONING AN ILLUMINATION DEVICE IN AN APPROPRIATE DISTANCE AND ILLUMINATING THE TREATMENT AREA WITH NARROWBAND RED LIGHT | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,235,169
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3195112 | ⤷ Try a Trial | |||
| China | 116507387 | ⤷ Try a Trial | |||
| European Patent Office | 4228745 | ⤷ Try a Trial | |||
| Japan | 2023545490 | ⤷ Try a Trial | |||
| South Korea | 20230088755 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
